Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells

Molecular and Cellular Endocrinology

Volumn 323, Issue 2, 2010, Pages 239-245

  Schayek, Hagit ^a   Seti, Hila ^a   Greenberg, Norman M ^b   Sun, Shihua ^c   Werner, Haim ^a   Plymate, Stephen R ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Androgen receptor; IGF I receptor; Insulin like growth factor I (IGF I); Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; MESSENGER RNA; MUTANT PROTEIN; SOMATOMEDIN C RECEPTOR; AR PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; CASTRATION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PROSTATE TUMOR; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CASTRATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, SCID; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RECEPTORS, ANDROGEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 77952951956     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.04.017     Document Type: Article

References (49)

1. Akalin A., Elmore L.W., Forsythe H.L., Amaker B.A., McCollum E.D., Nelson P.S., Ware J.L., Holt S.E. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Res. 2001, 61:4791-4796.
2. Bae V.L., Jackson-Cook C.K., Brothman A.R., Maygarden S.J., Ware J.L. Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int. J. Cancer 1994, 58:721-729.
3. Bae V.L., Jackson-Cook C.K., Maygarden S.J., Plymate S.R., Chen J., Ware J.L. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 1998, 34:275-282.
4. Bakin R.E., Gioeli D., Sikes R.A., Bissonette E.A., Weber M.J. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 2003, 63:1981-1989.
5. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563-566.
6. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
7. Chott A., Sun Z., Morganstern D., Pan J., Li T., Susani M., Mosberger I., Upton M.P., Bubley G.J., Balk S.P. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of type 1 insulin-like growth factor receptor. Am. J. Pathol. 1999, 155:1271-1279.
8. Cohen P., Peehl D.M., Lamson G., Rosenfeld R.G. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab. 1991, 73:401-407.
9. Corey E., Quinn J.E., Bladou F., Brown L.G., Roudier M.P., Brown J.M., Buhler K.R., Vessella R.L. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002, 52:20-33.
10. Corey E., Quinn J.E., Buhler K.R., Nelson P.S., Macoska J.A., True L.D., Vessella R.L. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 2003, 55:239-246.
11. Culig Z., Hobisch A., Cronauer M., Radmayr C., Hittmair A., Bartsch G., Klocker H. Andogen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994, 54:5474-5478.
12. Culig Z., Hobisch A., Cronauer M.V., Cato A.C., Hittmair A., Radmayr C., Eberle J., Bartsch G., Klocker H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 1993, 7:1541-1550.
13. Damon S.E., Plymate S.R., Carroll J.M., Sprenger C.C., Dechsukhum C., Ware J.L., Roberts C.T. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 2001, 142:21-27.
14. Deutsch E., Maggiorella L., Eschwege P., Bourhis J., Soria J.C., Abdulkarim B. Environmental, genetic and molecular features of prostate cancer. Lancet Oncol. 2004, 5:303-313.
15. DiGiovanni J., Kiguchi K., Frijhoff A., Wilker E., Bol D.K., Beltran L., Moats S., Ramirez A., Jorcano J., Conti C. Deregulated expression of insulin-like growth factor I in prostate epithelium leads to neoplasia in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:3455-3460.
16. Gelmann E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 2002, 20:3001-3015.
17. Grossmann M.E., Huang H., Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst. 2001, 93:1687-1697.
18. Han G., Buchanan G., Ittmann M., Harris J.M., Yu X., Demayo F.J., Tilley W.D., Greenberg N.M. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1151-1156.
19. Hellawell G.O., Turner G.D., Davies D.R., Poulsom R., Brewster S.F., Macaulay V.M. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 2002, 62:2942-2950.
20. Kaplan P.J., Mohan S., Cohen P., Foster B.A., Greenberg N.M. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res. 1999, 59:2203-2209.
21. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 2000, 21:215-244.
22. Lee H.J., Chang C. Recent advances in androgen receptor action. Cell. Mol. Life Sci. 2003, 60:1613-1622.
23. Lin H.K., Yeh S., Kang H.Y., Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:7200-7205.
24. Marcelli M., Ittmann M., Mariani S., Sutherland R., Nigam R., Murthy L., Zhao Y., DiConcini D., Puxeddu E., Esen A., Eastham J., Weigel N.L., Lamb D.J. Androgen receptor mutations in prostate cancer. Cancer Res. 2000, 60:944-949.
25. Moehren U., Papaioannou M., Reeb C.A., Grasselli A., Nanni S., Asim M., Roell D., Prade I., Farsetti A., Baniahmad A. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development. FASEB J. 2008, 22:1258-1267.
26. Nickerson T., Chang F., Lorimer D., Smeekens S.P., Sawyers C.L., Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 2001, 61:6276-6280.
27. Orio F., Terouanne B., Georget V., Lumbroso S., Avances C., Siatka C., Sultan C. Potential action of IGF-I and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Mol. Cell. Endocrinol. 2002, 198:105-114.
28. Pandini G., Mineo R., Frasca F., Roberts C.T., Marcelli M., Vigneri R., Belfiore A. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res. 2005, 65:1849-1857.
29. Plymate S., Bae V., Madison L., Quinn L., Ware J.L. Re-expression of the type I IGF receptor inhibits the malignant phenotype of simian virus 40 T antigen inmortalized human prostate epithelial cells. Endocrinology 1997, 138:1728-1735.
30. Plymate S.R., Haugk K., Coleman I., Woodke L., Vessella R., Nelson P., Montgomery R.B., Ludwig D.L., Wu J.D. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin. Cancer Res. 2007, 13:6429-6439.
31. Plymate S.R., Tennant M., Birnbaum R.S., Thrasher J.B., Chatta G., Ware J.L. The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J. Clin. Endocrinol. Metab. 1996, 81:3709-3716.
32. Plymate S.R., Tennant M.K., Culp S.H., Woodke L., Marcelli M., Coleman I., Nelson P.S., Carroll J.M., Roberts C.T., Ware J.L. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 2004, 61:276-290.
33. Roddam A.W., Allen N.E., Appleby P., Key T.J., Ferrucci L., Carter H.B., Metter E.J., Chen C., Weiss N.S., Fitzpatrick A., et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann. Intern. Med. 2008, 149:461-471.
34. Ruan W., Powell-Braxton L., Kopchick J.J., Kleinberg D.L. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 1999, 140:1984-1989.
35. Rubinstein M., Idelman G., Plymate S.R., Narla G., Friedman S.L., Werner H. Transcriptional activation of the IGF-I receptor gene by the Kruppel-like factor-6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. Endocrinology 2004, 145:3769-3777.
36. Samani A.A., Yakar S., LeRoith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 2007, 28:20-47.
37. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 2005, 23:8253-8261.
38. Schroder F.H. Endocrine therapy for prostate cancer: recent developments and current status. Br. J. Urol. 1993, 71:633-640.
39. Shi X.B., Ma A.H., Xia L., Kung H., de Vere White R.W. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002, 62:1496-1502.
40. Sun C., Shi Y., Xu L.L., Nageswararao C., Davis L.D., Segawa T., Dobi A., McLeod D.G., Srivastava S. Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 2006, 25:3905-3913.
41. Sutherland B.W., Knoblaugh S.E., Kaplan-Lefko P.J., Wang F., Holzenberger M., Greenberg N.M. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res. 2008, 68:3495-3504.
42. Tennant M.K., Thrasher J.B., Twomey P.A., Drivdahl R.H., Birnbaum R.S., Plymate S.R. Protein and mRNA for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab. 1996, 81:3774-3782.
43. Veldscholte J., Ris-Stalpers C., Kuiper G.G., Jenster G., Berrevoets C., Claassen E., van Rooij H.C., Trapman J., Brinkmann A.O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 1990, 173:534-540.
44. Werner H., Adamo M., Roberts C.T., LeRoith D. Molecular and cellular aspects of insulin-like growth factor action. Vitamins Hormones 1994, 48:1-58.
45. Werner H., Idelman G., Rubinstein M., Pattee P., Nagalla S.R., Roberts C.T. A novel EWS-WT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Cancer Lett. 2007, 247:84-90.
46. Werner H., Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol. Metab. 2006, 17:236-242.
47. Wu J.D., Haugk K., Coleman I., Woodke L., Vessella R., Nelson P., Montgomery R.B., Ludwig D.L., Plymate S.R. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin. Cancer Res. 2006, 12:6153-6160.
48. Wu J.D., Haugk K., Woodke L., Nelson P., Coleman I., Plymate S.R. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J. Cell. Biochem. 2006, 99:392-401.
49. Wu J.D., Odman A., Higgins L.M., Haugk K., Vessella R., Ludwig D.L., Plymate S.R. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin. Cancer Res. 2005, 11:3065-3074.